ArticleAfrican journal of laboratory medicine2025
Association of obesity with hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.
Article in African journal of laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between a high total cholesterol-to-high-density lipoprotein cholesterol ratio and hyperuricemia among patients with hypertension: A cross-sectional study from central Uganda.The Journal of international medical research · 2026Article
- Magnitude of Hyperuricemia and Its Associated Factors Among People Living with Human Immunodeficiency Virus Who Enrolled in First-Line Antiretroviral Therapy in Amhara Region, Ethiopia.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperuricaemia is a risk factor for gout and independently predicts hypertension, diabetes, and chronic kidney disease development. While elevated uric acid levels occur in HIV patients, and weight gain is linked to dolutegravir-based therapy, data on the obesity-hyperuricaemia relationship in this population remain limited. Objective: The objective of our study was to evaluate the association between obesity and hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda. Methods: Between April 2024 and June 2024, this study conducted a secondary analysis of data on uric acid level and factors associated with obesity from a 2023 cross-sectional study of HIV-positive participants. We used logistic regression to assess the factors associated with hyperuricaemia, and receiver operating characteristic curve analysis to assess the predictive performance of body mass index for hyperuricaemia. Results: Among 328 participants, hyperuricaemia prevalence was 23.48% (95% confidence interval [CI]: 19.19-28.39%) higher in male participants (31.6%) than female participants (20.0%, Conclusion: Our findings indicate a relationship between hyperuricaemia and obesity in HIV patients on antiretroviral therapy in Uganda. Nationwide studies using primary data are needed to better understand this relationship's epidemiological spread. What this study adds: This study is the first to link obesity with hyperuricaemia among HIV-positive Ugandans on antiretroviral therapy, highlighting obesity as a key metabolic complication of HIV treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.